PTPN11 and KRAS gene analysis in patients with noonan and noonan-like syndromes

Genetic Testing and Molecular Biomarkers

Volumn 14, Issue 3, 2010, Pages 425-432

  Brasil, Amanda Salem ^a   Pereira, Alexandre C ^b   Wanderley, Luciana Turolla ^a   Kim, Chong Ae ^a   Malaquias, Alexsandra C ^c   Jorge, Alexander A L ^c   Krieger, José Eduardo ^b   Bertola, Débora Romeo ^a  

^a Unidade de Genética Instituto da Criança Hospital das Clý nicas   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Laboratorio de Genetica Molecular do Cancer   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE PHOSPHATASE SHP 2; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PTPN11 PROTEIN, HUMAN; RAS PROTEIN;

ADOLESCENT; ADULT; ARTICLE; CARDIOFACIOCUTANEOUS SYNDROME; CENTRAL NERVOUS SYSTEM MALFORMATION; CHILD; CLINICAL FEATURE; CONGENITAL HEART DISEASE; COSTELLO SYNDROME; CRYPTORCHISM; DEVELOPMENTAL DISORDER; DNA POLYMORPHISM; EYEBROW; FEMALE; GENE MUTATION; HAIR; HEMATOLOGIC DISEASE; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; MUTATIONAL ANALYSIS; NECK MALFORMATION; NEUROFIBROMATOSIS NOONAN SYNDROME; NOONAN SYNDROME; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS; PALMOPLANTAR KERATODERMA; PRESCHOOL CHILD; PREVALENCE; PULMONARY VALVE STENOSIS; SCHOOL CHILD; SHORT STATURE; THORAX MALFORMATION; VERTEBRA MALFORMATION; GENETICS; GENOTYPE; MUTATION; PATHOPHYSIOLOGY; PHENOTYPE; SYNDROME; YOUNG ADULT;

RATTUS;

ADOLESCENT; ADULT; CARDIOMYOPATHY, HYPERTROPHIC; CHILD; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; FEMALE; GENOTYPE; HUMANS; MALE; MUTATION; NOONAN SYNDROME; PHENOTYPE; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; PROTO-ONCOGENE PROTEINS; PULMONARY VALVE STENOSIS; RAS PROTEINS; SYNDROME; YOUNG ADULT;

EID: 77954937826     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2009.0192     Document Type: Article

References (53)

1. Aoki Y, Niihori T, Kawame H, et al. (2005) Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet 37:1038-1040.
2. Aoki Y, Niihori T, Narumi Y, et al. (2008) The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. Hum Mutat 29:992-1006.
3. Bertola DR, Pereira AC, Albano LM, et al. (2006) PTPN11 gene analysis in 74 Brazilian patients with Noonan syndrome or Noonan-like phenotype. Genet Test 10:186-191.
4. Bertola DR, Pereira AC, Brasil AS, et al. (2007) Further evidence of genetic heterogeneity in Costello syndrome: involvement of the KRAS gene. J Hum Genet 52:521-526.
5. Bertola DR, Pereira AC, Passetti F, et al. (2005) Neurofibromatosis- Noonan syndrome: molecular evidence of the concurrence of both disorders in a patient. Am J Med Genet A 136:242-245.
6. Carta C,PantaleoniF,BocchinfusoG,et al.(2006) Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype. Am J Hum Genet 79:129-135.
7. Danoviz ME, Pereira AC, Mill JG, Krieger JE (2006) Hypertension, obesity and GNB 3 gene variants. Clin Exp Pharmacol Physiol 33:248-252.
8. De Luca A, Bottillo I, Sarkozy A, et al. (2005) NF1 gene mutations represent the major molecular event underlying neurofibro-matosis-Noonan syndrome. Am J Hum Genet 77:1092-1101.
9. Digilio MC, Conti E, Sarkozy A, et al. (2002) Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. Am J Hum Genet 71:389-394.
10. Elce A, Boccia A, Cardillo G, et al. (2009) Three novel CFTR polymorphic repeats improve segregation analysis for cystic fibrosis. Clin Chem 55:1372-1379.
11. ESE Finder (2009) A web resource to identify exonic splicing enhancers. http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi? process/home
12. Ferrero GB, Baldassarre G, Delmonaco AG, et al. (2008) Clinical and molecular characterization of 40 patients with Noonan syndrome. Eur J Med Genet 51:566-572.
13. GeneBee\Molecular Biology Server (2009) RNA secondary structure prediction. www.genebee.msu.su/services/rna2-reduced.html
14. GeneSplicer (2009) A computational method for splice site prediction. www.cbcb.umd.edu/software/GeneSplicer/gene-spl.shtml
15. Gripp KW (2005) Tumor predisposition in Costello syndrome. Am J Med Genet C Semin Med Genet 137C:72-77.
16. Ion A, Tartaglia M, Song X, et al. (2002) Absence of PTPN11 mutations in 28 cases of cardiofaciocutaneous (CFC) syndrome. Hum Genet 111:421-427.
17. Kalidas K, Shaw AC, Crosby AH, et al. (2005) Genetic heterogeneity in LEOPARD syndrome: two families with no mutations in PTPN11. J Hum Genet 50:21-25.
18. Kavamura MI, Pomponi MG, Zollino M, et al. (2003) PTPN11 mutations are not responsible for the Cardiofaciocutaneous (CFC) syndrome. Eur J Hum Genet 11:64-68.
19. Keren B, Hadchouel A, Saba S, et al. (2004) PTPN11 mutations in patients with LEOPARD syndrome: a French multicentric experience. J Med Genet 41:e117.
20. Kerr B, Delrue MA, Sigaudy S, et al. (2006) Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases. J Med Genet 43:401-405.
21. Ko JM, Kim JM, Kim GH, Yoo HW (2008) PTPN11, SOS1, KRAS, and RAF1 gene analysis, and genotype-phenotype correlation in Korean patients with Noonan syndrome. J Hum Genet 53:999-1006.
22. Lee ST, Ki CS, Lee HJ (2007) Mutation analysis of the genes involved in the Ras-mitogen-activated protein kinase (MAPK) pathway in Korean patients with Noonan syndrome. Clin Genet 72:150-155.
23. Levy H, Murphy A, Zou F, et al. (2009) IL1B polymorphisms modulate cystic fibrosis lung disease. Pediatr Pulmonol 44: 580-593.
24. Lo FS, Lin JL, Kuo MT, et al. (2009) Noonan syndrome caused by germline KRAS mutation in Taiwan: report of two patients and a review of the literature. Eur J Pediatr 168:919-923.
25. Marquezine GF, Oliveira CM, Pereira AC, et al. (2008) Metabolic syndrome determinants in an urban population from Brazil: social class and gender-specific interaction. Int J Cardiol 129: 259-265.
26. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215.
27. Musante L, Kehl HG, Majewski F, et al. (2003) Spectrum of mutations in PTPN11 and genotype-phenotype correlation in 96 patients with Noonan syndrome and five patients with cardio-facio-cutaneous syndrome. Eur J Hum Genet 11: 201-206.
28. Nava C, Hanna N, Michot C, et al. (2007) Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome. J Med Genet 44:763-771.
29. Niihori T, Aoki Y, Narumi Y, et al. (2006) Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet 38:294-296.
30. Noonan JA (1994) Noonan syndrome. An update and review for the primary pediatrician. Clin Pediatr (Phila) 33:548-555.
31. Nystrom AM, Ekvall S, Berglund E, et al. (2008) Noonan and cardio-facio-cutaneous syndromes: two clinically and genetically overlapping disorders. J Med Genet 45:500-506.
32. Pandit B, Sarkozy A, Pennacchio LA, et al. (2007) Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet 39: 1007-1012.
33. Pereira AC, Floriano MS, Mota GF, et al. (2003a) Beta2 adreno-ceptor functional gene variants, obesity, and blood pressure level interactions in the general population. Hypertension 42:685-692.
34. Pereira AC, Mota GF, Cunha RS, et al. (2003b) Angiotensinogen 235T allele "dosage" is associated with blood pressure phe-notypes. Hypertension 41:25-30.
35. Polyphen (2009) (Polymorphism phenotyping) at European Molecular Biology Laboratory, Heidelberg, Germany. http://genetics.bwh.harvard.edu/pph/
36. Razzaque MA, Nishizawa T, Komoike Y, et al. (2007) Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat Genet 39:1013-1017.
37. Rodriguez-Viciana P, Tetsu O, Tidyman WE, et al. (2006) Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 311:1287-1290.
38. Sarkozy A, Carta C, Moretti S, et al. (2009) Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum. Hum Mutat 30:695-702.
39. Sarkozy A, Digilio MC, Dallapiccola B (2008) Leopard syndrome. Orphanet J Rare Dis 3:13.
40. Schubbert S, Zenker M, Rowe SL, et al. (2006) Germline KRAS mutations cause Noonan syndrome. Nat Genet 38:331-336.
41. Seishima M, Mizutani Y, Shibuya Y, et al. (2007) Malignant melanoma in a woman with LEOPARD syndrome: identification of a germline PTPN11 mutation and a somatic BRAF mutation. Br J Dermatol 157:1297-1299.
42. Sharland M, Burch M, McKenna WM, Paton MA (1992) A clinical study of Noonan syndrome. Arch Dis Child 67:178-183.
43. Sovik O, Schubbert S, Houge G, et al. (2007) De novo HRAS and KRAS mutations in two siblings with short stature and neuro-cardio-facio-cutaneous features. J Med Genet 44:e84.
44. Sunyaev S, Ramensky V, Koch I, et al. (2001) Prediction of deleterious human alleles. Hum Mol Genet 10:591-597.
45. Tartaglia M, Kalidas K, Shaw A, et al. (2002) PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet 70:1555-1563.
46. Tartaglia M, Mehler EL, Goldberg R, et al. (2001) Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 29:465-468.
47. Tartaglia M, Pennacchio LA, Zhao C, et al. (2007) Gain-of-func-tion SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet 39:75-79.
48. Thiel C, Wilken M, Zenker M, et al. (2009) Independent NF1 and PTPN11 mutations in a family with neurofibromatosis-Noonan syndrome. Am J Med Genet A 149A:1263-1267.
49. van der Burgt I, Berends E, Lommen E, et al. (1994) Clinical and molecular studies in a large Dutch family with Noonan syndrome. Am J Med Genet 53:187-191.
50. VISTA Genome Browser (2009) Computational tools for comparative genomics. http://pipeline.lbl.gov/cgi-bin/gateway2
51. Yoshida R, Hasegawa T, Hasegawa Y, et al. (2004) Protein-tyrosine phosphatase, nonreceptor type 11 mutation analysis and clinical assessment in 45 patients with Noonan syndrome. J Clin Endocrinol Metab 89:3359-3364.
52. Zenker M, Buheitel G, Rauch R, et al. (2004) Genotype-phenotype correlations in Noonan syndrome. J Pediatr 144:368-374.
53. Zenker M, Lehmann K, Schulz AL, et al. (2007) Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations. J Med Genet 44:131-135.